FDA Panel Endorses Onyx Pharmaceuticals' Blood Cancer Drug

Law360, Washington (June 20, 2012, 5:25 PM EDT) -- A U.S. Food and Drug Administration advisory committee on Wednesday strongly recommended that the FDA approve Onyx Pharmaceuticals Inc.'s multiple myeloma drug carfilzomib, saying it looked forward to seeing results from the company's additional clinical trials for the treatment.

In an 11-0 vote with one abstention, the FDA's Oncologic Drugs Advisory Committee praised Onyx for delivering a strong risk-benefit profile for carfilzomib injections, which would be a third-line treatment for the blood cancer. According to the FDA and Onyx, 23 percent of patients in the company's...
To view the full article, register now.